Is genetic polymorphism of XRCC1 Arg399Gln associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum?
Genetic polymorphism of XRCC1 Arg399Gln may be a candidate for contributing interindividual difference in the OS of gemcitabine/platinum-treated advanced NSCLC patients.
Luxation after canine THR is a multifactorial problem but preexisting subluxation/soft tissue laxity is a significant risk factor for this complication.